Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Expenses (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Operating Expenses for 10 consecutive years, with $320.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 11.71% to $320.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 10.22% year-over-year, with the annual reading at $1.2 billion for FY2025, 10.22% up from the prior year.
  • Operating Expenses for Q4 2025 was $320.6 million at Ultragenyx Pharmaceutical, down from $330.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $330.8 million in Q3 2025, with the low at $169.8 million in Q2 2021.
  • Average Operating Expenses over 5 years is $252.6 million, with a median of $255.4 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 84.15% in 2022, then decreased 23.0% in 2023.
  • Over 5 years, Operating Expenses stood at $186.0 million in 2021, then skyrocketed by 33.89% to $249.0 million in 2022, then increased by 0.0% to $249.0 million in 2023, then grew by 15.25% to $287.0 million in 2024, then increased by 11.71% to $320.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $320.6 million, $330.8 million, and $274.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.